Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Please Try Again

Password Hint : {{passwordHint}}

Remember me

Cardiol Therapeutics Inc CRDL

Primary Symbol: T.CRDL

Healthcare

Cardiol Therapeutics Inc. is a clinical-stage life sciences company. The Company is focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. Its lead drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure. It is also developing CRD-38, a novel subcutaneously administered drug intended for use in heart failure. It has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart.

TSX:CRDL - Post by User

Cardiol Therapeutics Inc > Mengel Updated Recommendation on CRDL

<< Previous

Bullboard Posts

Next >>

Comment by Mapleleaf57on Apr 21, 2021 6:56pm

114 Views

Post# 33041924

RE:Mengel Updated Recommendation on CRDL

June 10, 2019 - 11:55 PM

79 Reads

Post# 29814095

RE:Cannabis Investors (stock exchange)

FYI.....If you want to know the full potential of CRDL, it’s covered really well by Jimmy Mengel - the Marijuana Manifesto (The Outsiders Club), it’s worth the subscription! Also covered really well by AltaCorp Capital. Just saying....

Seems you like promoting Jimmy Mengel also,,, Just saying this is a post from 2019

<< Previous

Bullboard Posts

Next >>

Junior helium stock to benefit from new legislation in U.S.